chemotherapy initiated between January 2016 and August 2018. PP pGCSF use was appropriate if prescribed with chemotherapy regimens with a high risk (>20%) for FN, or intermediate risk (10%–20%) if other accepted FN risk factors were present. PP use with FN low
Search Results
BPI19-015: Reduction of Inappropriate Prophylactic Pegylated Granulocyte Colony-Stimulating Factor (pGCSF) Use for Lung Cancer Patients: Five-Year Follow Up of a Quality Improvement (QI) Initiative at the Cleveland Clinic Taussig Cancer Institute (TCI)
Anne K. Hubben, Nathan Pennell, Marc Shapiro, Craig Savage, and James P. Stevenson
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology
Douglas E. Wood, Ella A. Kazerooni, Scott L. Baum, George A. Eapen, David S. Ettinger, Lifang Hou, David M. Jackman, Donald Klippenstein, Rohit Kumar, Rudy P. Lackner, Lorriana E. Leard, Inga T. Lennes, Ann N.C. Leung, Samir S. Makani, Pierre P. Massion, Peter Mazzone, Robert E. Merritt, Bryan F. Meyers, David E. Midthun, Sudhakar Pipavath, Christie Pratt, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Peter B. Sachs, Matthew B. Schabath, Mark L. Schiebler, Betty C. Tong, William D. Travis, Benjamin Wei, Stephen C. Yang, Kristina M. Gregory, and Miranda Hughes
The NCCN Guidelines 1) describe risk factors for lung cancer; 2) recommend criteria for selecting individuals with high-risk factors for screening; 3) provide recommendations for evaluation and follow-up of lung nodules found during screening; 4
Evidence and Controversies in the Use of Post-Mastectomy Radiation
Shaneli A. Fernando and Stephen B. Edge
with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials . J Clin Oncol 2004 ; 22 : 4247 – 4254 . 7. Wallgren A Bonetti M Gelber RD . Risk factors
Management of Toxicities of BTK Inhibitors in B-Cell Malignancies
Presented by: Muhammad Saad Hamid and Kirollos S. Hanna
bleeding in critical areas. Risk factors for bleeding include concurrent use of antiplatelet and anticoagulant drugs, with the strongest data linked to antiplatelet therapy. The use of warfarin, in particular, has been contraindicated with ibrutinib and
Breast Cancer Risk Reduction Clinical Practice Guidelines in Oncology
Breast cancer risk factor analysis allows the identification of women at very high risk for the future development of breast cancer. However, estimating risk for the individual woman is difficult, and most breast cancers are not attributable to risk factors other than female gender and increased age. These practice guidelines discuss known risk factors, strategies for reducing risk, and possible future developments.
For the most recent version of the guidelines, please visit NCCN.org
VTE as a Quality Indicator
Myron Goldsmith, George Whitelaw, and Denise A. Cannaday
. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients . Cancer 2007 ; 110 : 2339 – 2346 . 11. Wagman LD Baird MF Bennett CL . NCCN Clinical Practice Guidelines in Oncology: Venous Thromboembolic
Current Concepts in Penile Cancer
Philippe E. Spiess, Simon Horenblas, Lance C. Pagliaro, Matthew C. Biagioli, Juanita Crook, Peter E. Clark, Richard E. Greenberg, and Cesar E. Ercole
/print certificate. Release date: May 13, 2013; Expiration date: May 13, 2014. Learning Objectives Upon completion of this activity, participants will be able to: Identify the risk factors associated with penile cancer. Discuss the rationale for
Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab
Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Andrew Rowland, Ashley M. Hopkins, and Michael J. Sorich
patients with non–small cell lung cancer treated using atezolizumab monotherapy, we analyzed the incidence, severity, time course, treatment, outcomes, and risk factors of various organ-specific irAEs and their relationships with response rates
New Persistent Opioid and Benzodiazepine Use After Curative-Intent Treatment in Patients With Breast Cancer
Mandy R. Sakamoto, Megan Eguchi, Christine M. Azelby, Jennifer R. Diamond, Christine M. Fisher, Virginia F. Borges, Cathy J. Bradley, and Peter Kabos
treatment remains high. We performed a retrospective cohort analysis using population-based data to evaluate new and persistent opioid and benzodiazepine use and risk factors among patients with breast cancer who received curative-intent treatment. Methods
Hepatic Epithelioid Hemangioendothelioma in a Patient With Hemochromatosis
Nisar Ahmad, Denise M. Adams, Jiang Wang, Rajan Prakash, and Nagla Abdel Karim
,000. 3 It is slightly more common in women, with a female-to-male ratio of approximately 1.6:1.0. Risk factors for HEHE are not well-known. An association of HEHE with oral contraceptives has been suggested but not completely established. 4 , 5 HEHE
